<?xml version="1.0" encoding="UTF-8"?>
<p id="Par20">Results of phase 3 randomized trials have shown consistently that post-ASCT lenalidomide maintenance therapy significantly extends the duration of remission as compared with no maintenance therapy [
 <xref ref-type="bibr" rid="CR5">5</xref>, 
 <xref ref-type="bibr" rid="CR8">8</xref>, 
 <xref ref-type="bibr" rid="CR10">10</xref>, 
 <xref ref-type="bibr" rid="CR29">29</xref>]. Recently, a meta-analysis of three phase 3 trials showed a significant OS benefit for lenalidomide maintenance therapy versus no maintenance therapy [
 <xref ref-type="bibr" rid="CR17">17</xref>]. With significant improvements in PFS, results of the Myeloma XI study (
 <italic>N</italic> = 1550) support use of maintenance lenalidomide as standard of care regardless of patient age [
 <xref ref-type="bibr" rid="CR22">22</xref>]. Although rates of hematologic AEs and discontinuation because of AEs reported have been higher for patients receiving lenalidomide maintenance therapy compared with placebo, the general toxicity profile is manageable [
 <xref ref-type="bibr" rid="CR8">8</xref>, 
 <xref ref-type="bibr" rid="CR10">10</xref>]. Second primary malignancies were higher for patients receiving lenalidomide maintenance therapy; however, when compared with the meaningful survival improvement, the benefit–risk profile remained positive [
 <xref ref-type="bibr" rid="CR17">17</xref>]. However, PROs were not collected in these studies; therefore, HRQoL outcomes were not adequately assessed.
</p>
